Related Experiment Video
Updated: May 5, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Review of depot aripiprazole for schizophrenia
Farha Bilal Motiwala1, Kim Stasia Siscoe, Rif S El-Mallakh
1Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA.
Abstract:
Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will be available soon. A review of all publically available information on depot aripiprazole as of November 2012 was performed. One peer-reviewed study on depot aripiprazole is published, and the remainder of the data were presented at international scientific meetings. Depot aripiprazole appears to be both safe and effective in the long-term treatment of schizophrenia.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

